The genomic landscape of response to EGFR blockade in colorectal cancer
A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou… - Nature, 2015 - nature.com
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients
diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted …
diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted …
The genomic landscape of response to EGFR blockade in colorectal cancer
A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou… - Nature, 2015 - econpapers.repec.org
EconPapers: The genomic landscape of response to EGFR blockade in colorectal cancer
EconPapers Economics at your fingertips EconPapers Home About EconPapers Working …
EconPapers Economics at your fingertips EconPapers Home About EconPapers Working …
The genomic landscape of response to EGFR blockade in colorectal cancer
A Bertotti, E Papp, S Jones, V Adleff… - … weekly journal of …, 2015 - dialnet.unirioja.es
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients
diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted …
diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted …
[引用][C] The genomic landscape of response to EGFR blockade in colorectal cancer
A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou… - Nature, 2015 - ideas.repec.org
The genomic landscape of response to EGFR blockade in colorectal cancer IDEAS home
Advanced search Economic literature: papers, articles, software, chapters, books. Authors …
Advanced search Economic literature: papers, articles, software, chapters, books. Authors …
The genomic landscape of response to EGFR blockade in colorectal cancer
A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou… - NATURE, 2015 - iris.unito.it
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients
diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted …
diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted …
The genomic landscape of response to EGFR blockade in colorectal cancer
A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou… - Nature, 2015 - go.gale.com
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients
diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted …
diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted …
The genomic landscape of response to EGFR blockade in colorectal cancer
A Bertotti, E Papp, S Jones, V Adleff… - …, 2015 - pubmed.ncbi.nlm.nih.gov
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients
diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted …
diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted …
[引用][C] The genomic landscape of response to EGFR blockade in colorectal cancer
A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou… - Nature, 2015 - cir.nii.ac.jp
The genomic landscape of response to EGFR blockade in colorectal cancer | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文 …
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文 …
The genomic landscape of response to EGFR blockade in colorectal cancer.
A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou… - …, 2015 - search.ebscohost.com
Colorectal cancer is the third most common cancer worldwide, with 1.2 million patients
diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted …
diagnosed annually. In late-stage colorectal cancer, the most commonly used targeted …
The genomic landscape of response to EGFR blockade in colorectal cancer.
A Bertotti, E Papp, S Jones, V Adleff, V Anagnostou… - Nature, 2015 - europepmc.org
Colorectal cancer (CRC) is the third most common cancer world-wide with 1.2 million
patients diagnosed yearly. In late stage CRC, the most commonly used targeted therapies …
patients diagnosed yearly. In late stage CRC, the most commonly used targeted therapies …